<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95875">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042456</url>
  </required_header>
  <id_info>
    <org_study_id>124.03-2013-GES-0003</org_study_id>
    <nct_id>NCT02042456</nct_id>
  </id_info>
  <brief_title>Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts</brief_title>
  <official_title>Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating whether automated whole breast ultrasound can improve detection
      of cancer in breast cancer screening when used as a supplement to mammography or as a
      supplement to digital breast tomosynthesis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Abnormal interpretation rate</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Abnormal interpretation rates for each modality (FFDM and DBT+V-Preview, with and without ABUS+V-Preview).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specificity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Rate</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cancer Rate will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>One Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Negative Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Main Cohort</arm_group_label>
    <description>Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital Breast Tomosynthesis</intervention_name>
    <description>digital breast tomosynthesis technology</description>
    <arm_group_label>Main Cohort</arm_group_label>
    <other_name>GE SenoClaire DBT with V-Preview</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Automated Whole Breast Ultrasound</intervention_name>
    <description>Automated Whole Breast Ultrasound</description>
    <arm_group_label>Main Cohort</arm_group_label>
    <other_name>Invenia ABUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Full Field Digital Mammography</intervention_name>
    <arm_group_label>Main Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from the patients arriving at the clinic for yearly breast
        cancer screening exams
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide signed declaration of informed consent or have a legally
             authorized representative provide signed declaration of informed consent for
             participation in all study procedures;

          -  Women aged â‰¥18 years at the time of enrollment;*

          -  Women with a previous determination of dense breasts determined by mammogram as
             heterogeneously dense or extremely dense; AND

          -  At moderately increased or high risk (&gt;15% lifetime risk) for breast cancer based on
             meeting one or more of the ACS criteria 1:

               1. BRCA1 or BRCA2 gene mutation;

               2. first-degree relative with BRCA1 or BRCA2 gene mutation (based on subject
                  self-report) and have not had genetic testing themselves;

               3. radiation therapy to the chest between ages 10 and 30 years;

               4. Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, or
                  one of these syndromes in a first-degree relative;

               5. previous diagnosis of breast cancer, ductal carcinoma in situ (DCIS), lobular
                  carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia.

        Exclusion Criteria:

          -  Have been screened using any breast imaging technology in &lt;12 months immediately
             prior to enrollment;

          -  Exhibit breast cancer symptoms according to assessment by the subject's health care
             provider within one year prior to enrollment;

          -  Diagnosed with breast cancer, with or without metastasis, within one year prior to
             enrollment;

          -  Are currently pregnant based on urine pregnancy test;*

          -  Present with contraindications to any imaging examination required in the study
             protocol;

          -  Have breast implants;

          -  Are lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Kolb</last_name>
      <phone>206-288-6321</phone>
      <email>skolb@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Constance Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janie Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Habibollah Rahbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Scheel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>dense breasts</keyword>
  <keyword>mammography screening</keyword>
  <keyword>Screening techniques</keyword>
  <keyword>women</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
